Use of Topical Clascoterone for the Treatment of Hidradenitis Suppurativa

    April 2023 in “ JAAD Case Reports ”
    Kaitlynne N. Cunningham, Katherine Moody, May Alorainy, David Rosmarin
    Studysummary This article discusses the challenges in treating hidradenitis suppurativa, highlighting that adalimumab is currently the only FDA-approved treatment, and reports no clinical results.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on jaadcasereports.org →
    Discuss this study in the Community →

    Research cited in this study 4

    1. The Role of Hormones in Hidradenitis Suppurativa: A Systematic Review International Journal of Molecular Sciences · 2022
    2. Is There a Role for Antiandrogen Therapy for Hidradenitis Suppurativa? A Systematic Review of Published Data American Journal of Clinical Dermatology · 2019
    3. North American Clinical Management Guidelines for Hidradenitis Suppurativa: A Publication from the United States and Canadian Hidradenitis Suppurativa Foundations Journal of the American Academy of Dermatology · 2019
    4. Antiandrogen Therapy with Spironolactone for the Treatment of Hidradenitis Suppurativa Journal of The American Academy of Dermatology · 2018